Patent Grant
7151103
The invention relates to the use of flibanserin for the preparation of a medicament for the treatment of disorders of sexual desire.
The compound 1 -[2-(4-(3-trifluoromethyl-phenyl)piperazin-1-yl)ethyl]-2,3-dihydro-1H-benzimidazol -2- one (fibanserin) is disclosed in form of its hydrochloride in European Patent Application EP-A-526434 and has the following chemical structure:
Flibanserin shows affinity for the 5-HT1A and 5-HT2-receptor. It is therefore a promising therapeutic agent for the treatment of a variety of diseases, for instance depression, schizophrenia, and anxiety.
In studies of male and female patients suffering from sexual dysfunction it has been found that flibanserin optionally in form of the pharmacologically acceptable acid addition salts thereof displays sexual desire enhancing properties. Accordingly, the instant invention relates to the use of flibanserin, optionally in form of the pharmacologically acceptable acid addition salts thereof for the preparation of a medicament for the treatment of disorders of sexual desire.
In a preferred embodiment the invention relates to the use of flibanserin, optionally in form of the pharmacologically acceptable acid addition salts thereof for the preparation of a medicament for the treatment of disorders selected from the group consisting of Hypoactive Sexual Desire Disorder, loss of sexual desire, lack of sexual desire, decreased sexual desire, inhibited sexual desire, loss of libido, libido disturbance, and frigidity.
Particular preferred according to the invention is the use of flibanserin, optionally in form of the pharmacologically acceptable acid addition salts thereof for the preparation of a medicament for the treatment of disorders selected from the group consisting of Hypoactive Sexual Desire Disorder, loss of sexual desire, lack of sexual desire, decreased sexual desire, inhibited sexual desire.
In a particularity preferred embodiment the invention relates to the use of flibanserin, optionally in form of the pharmacologically acceptable acid addition salts thereof for the preparation of a medicament for the treatment of disorders selected from the group of Hypoactive Sexual Desire Disorder and loss of sexual desire.
The observed effects of flibanserin can be achieved in men and women. However, according to a further aspect of the invention the use of flibanserin optionally in form of the pharmacologically acceptable acid addition salts thereof for the preparation of a medicament for the treatment of female sexual dysfunction is preferred.
The beneficial effects of flibanserin can be observed regardless of whether the disturbance existed lifelong or was acquired, and independent of etiologic origin (organic—both, physically and drug induced-, psychogen, a combination of organic—both, physically and drug induced-, and psychogen, or unknown).
Flibanserin can optionally used in form of its pharmaceutically acceptable acid addition salts. Suitable acid addition salts include for example those of the acids selected from, succinic acid, hydrobromic acid, acetic acid, fumaric acid, maleic acid, methanesulphonic acid, lactic acid, phosphoric acid, hydrochloric acid, sulphuric acid, tartaric acid and citric acid. Mixtures of the abovementioned acid addition salts may also be used. From the aforementioned acid addition salts the hydrochloride and the hydrobromide, particularily the hydrochloride, are preferred.
Flibanserin, optionally used in form of its pharmaceutically acceptable acid addition salts, may be incorporated into the conventional pharmaceutical preparation in solid, liquid or spray form. The composition may, for example, be presented in a form suitable for oral, rectal, parenteral administration or for nasal inhalation: preferred forms includes for example, capsules, tablets, coated tablets, ampoules, suppositories and nasal spray. The active ingredient may be incorporated in excipients or carriers conventionally used in pharmaceutical compositions such as, for example, talc, arabic gum, lactose, gelatine, magnesium stearate, corn starch, acqueous or non acqueous vehicles, polyvynil pyrrolidone, semisynthetic glicerides of fatty acids, benzalconium chloride, sodium phosphate, EDTA, polysorbate 80. The compositions are advantageously formulated in dosage units, each dosage unit being adapted to supply a single dose of the active ingredient. The dosis range applicable per day is between 0.1 to 400, preferably between 1.0 to 300, more preferably between 2 to 200 mg. Each dosage unit may conveniently contain from 0.01 mg to 100 mg, preferably from 0.1 to 50 mg.
Suitable tablets may be obtained, for example, by mixing the active substance(s) with known excipients, for example inert diluents such as calcium carbonate, calcium phosphate or lactose, disintegrants such as corn starch or alginic acid, binders such as starch or gelatine, lubricants such as magnesium stearate or talc and/or agents for delaying release, such as carboxymethyl cellulose, cellulose acetate phthalate, or polyvinyl acetate. The tablets may also comprise several layers.
Coated tablets may be prepared accordingly by coating cores produced analogously to the tablets with substances normally used for tablet coatings, for example collidone or shellac, gum arabic, talc, titanium dioxide or sugar. To achieve delayed release or prevent incompatibilities the core may also consist of a number of layers. Similarly the tablet coating may consist of a number or layers to achieve delayed release, possibly using the excipients mentioned above for the tablets.
Syrups or elixirs containing the active substances or combinations thereof according to the invention may additionally contain a sweetener such as saccharine, cyclamate, glycerol or sugar and a flavour enhancer, e.g of. a flavouring such as vanilline or orange extract. They may also contain suspension adjuvants or thickeners such as sodium carboxymethyl cellulose, wetting agents such as, for example, condensation products of fatty alcohols with ethylene oxide, or preservatives such as p-hydroxybenzoates.
Solutions for injection are prepared in the usual way, e.g of. with the addition of preservatives such as p-hydroxybenzoates, or stabilisers such as alkali metal salts of ethylenediamine tetraacetic acid, and transferred into injection vials or ampoules.
Capsules containing one or more active substances or combinations of active substances may for example be prepared by mixing the active substances with inert carriers such as lactose or sorbitol and packing them into gelatine capsules.
Suitable suppositories may be made for example by mixing with carriers provided for this purpose, such as neutral fats or polyethyleneglycol or the derivatives thereof.
The Examples which follow illustrate the present invention without restricting its scope:
Examples of pharmaceutical formulations
The finely ground active substance, lactose and some of the corn starch are mixed together. The mixture is screened, then moistened with a solution of polyvinylpyrrolidone in water, kneaded, wet-granulated and dried. The granules, the remaining corn starch and the magnesium stearate are screened and mixed together. The mixture is compressed to produce tablets of suitable shape and size.
The finely ground active substance, some of the corn starch, lactose, microcrystalline cellulose and polyvinylpyrrolidone are mixed together, the mixture is screened and worked with the remaining corn starch and water to form a granulate which is dried and screened. The sodium-carboxy-methyl starch and the magnesium stearate are added and mixed in and the mixture is compressed to form tablets of a suitable size.
The active substance, corn starch, lactose and polyvinylpyrrolidone are thoroughly mixed and moistened with water. The moist mass is pushed through a screen with a 1 mm mesh size, dried at about 45° C. and the granules are then passed through the same screen. After the magnesium stearate has been mixed in, convex tablet cores with a diameter of 6 mm are compressed in a tablet-making machine. The tablet cores thus produced are coated in known manner with a covering consisting essentially of sugar and talc. The finished coated tablets are polished with wax.
The substance and corn starch are mixed and moistened with water. The moist mass is screened and dried. The dry granules are screened and mixed with magnesium stearate. The finished mixture is packed into size 1 hard gelatine capsules.
The active substance is dissolved in water at its own pH or optionally at pH 5.5 to 6.5 and sodium chloride is added to make it isotonic. The solution obtained is filtered free from pyrogens and the filtrate is transferred under aseptic conditions into ampoules which are then sterilised and sealed by fusion.
The hard fat is melted. At 40° C. the ground active substance is homogeneously dispersed. It is cooled to 38° C. and poured into slightly chilled suppository moulds.
| Number | Date | Country | Kind |
|---|---|---|---|
| 01125020 | Oct 2001 | EP | regional |
Benefit of U.S. Provisional Application Ser. No. 60/348,911, filed on Oct. 23, 2001 is hereby claimed, and said provisional application is herein incorporated by reference in its entirety.
| Number | Name | Date | Kind |
|---|---|---|---|
| 3406178 | Crocker et al. | Oct 1968 | A |
| 3472854 | Archer | Oct 1969 | A |
| 4200641 | Vandenberk et al. | Apr 1980 | A |
| 4737500 | Sorg | Apr 1988 | A |
| 4797399 | Ueda et al. | Jan 1989 | A |
| 4859692 | Bernstein et al. | Aug 1989 | A |
| 4886803 | Sueda et al. | Dec 1989 | A |
| 4940793 | Botre et al. | Jul 1990 | A |
| 4954503 | Strupczewski et al. | Sep 1990 | A |
| 5036088 | Kitaura et al. | Jul 1991 | A |
| 5576318 | Bietti et al. | Nov 1996 | A |
| 5883094 | Fliri et al. | Mar 1999 | A |
| 6281218 | Cereda et al. | Aug 2001 | B1 |
| 6284757 | Sanner | Sep 2001 | B1 |
| 6521623 | Cereda et al. | Feb 2003 | B1 |
| 6586435 | Cereda et al. | Jul 2003 | B1 |
| 20030060475 | Borsini | Mar 2003 | A1 |
| 20030083228 | Carpino et al. | May 2003 | A1 |
| 20030119850 | Bombarda et al. | Jun 2003 | A1 |
| 20040048877 | Friedl et al. | Mar 2004 | A1 |
| 20040180904 | Beck | Sep 2004 | A1 |
| 20040235861 | Borsini | Nov 2004 | A1 |
| 20050065158 | Naylor et al. | Mar 2005 | A1 |
| 20050159430 | Bombarda et al. | Jul 2005 | A1 |
| 20050239798 | Pyke | Oct 2005 | A1 |
| 20050245539 | Mendla et al. | Nov 2005 | A1 |
| 20060014757 | Pyke | Jan 2006 | A1 |
| 20060025420 | Brauns et al. | Feb 2006 | A1 |
| Number | Date | Country |
|---|---|---|
| 0200322 | Nov 1986 | EP |
| 0 526 434 | Feb 1993 | EP |
| 0705832 | Apr 1996 | EP |
| 0816356 | Jan 1998 | EP |
| 0982030 | Mar 2000 | EP |
| 1256343 | Nov 2002 | EP |
| 2023594 | Jan 1980 | GB |
| WO 95034555 | Dec 1995 | WO |
| WO 9842344 | Oct 1998 | WO |
| WO 200028993 | May 2000 | WO |
| WO 0121593 | Mar 2001 | WO |
| WO 03013539 | Feb 2003 | WO |
| WO 03014079 | Feb 2003 | WO |
| Number | Date | Country | |
|---|---|---|---|
| 20030104980 A1 | Jun 2003 | US |
| Number | Date | Country | |
|---|---|---|---|
| 60348911 | Oct 2001 | US |
